Acumen Pharmaceuticals, Inc.

NasdaqGS:ABOS Rapport sur les actions

Capitalisation boursière : US$170.9m

Acumen Pharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Acumen Pharmaceuticals's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 164.7% per year.

Informations clés

-8.5%

Taux de croissance des bénéfices

75.5%

Taux de croissance du BPA

Biotechs Croissance de l'industrie17.0%
Taux de croissance des recettes-164.7%
Rendement des fonds propres-26.6%
Marge netten/a
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 30

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Ventilation des recettes et des dépenses

Comment Acumen Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqGS:ABOS Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 240-65200
31 Mar 240-56200
31 Dec 230-52190
30 Sep 230-49170
30 Jun 230-46150
31 Mar 230-45140
31 Dec 220-43130
30 Sep 220-38120
30 Jun 220-32110
31 Mar 220-8390
31 Dec 210-10170
30 Sep 210-9350
30 Jun 211-9230
31 Mar 211-3220
31 Dec 201-710
31 Dec 192-810

Des revenus de qualité: ABOS is currently unprofitable.

Augmentation de la marge bénéficiaire: ABOS is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: ABOS is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.

Accélération de la croissance: Unable to compare ABOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: ABOS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement des fonds propres

ROE élevé: ABOS has a negative Return on Equity (-26.59%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé